A detailed history of Assenagon Asset Management S.A. transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 7,409 shares of AGIO stock, worth $412,533. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,409
Previous 134,980 94.51%
Holding current value
$412,533
Previous $5.82 Million 94.35%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$41.19 - $49.72 $5.25 Million - $6.34 Million
-127,571 Reduced 94.51%
7,409 $329,000
Q2 2024

Jul 18, 2024

SELL
$27.55 - $48.83 $8.81 Million - $15.6 Million
-319,821 Reduced 70.32%
134,980 $5.82 Million
Q1 2024

Apr 24, 2024

BUY
$21.32 - $34.81 $8.62 Million - $14.1 Million
404,297 Added 800.52%
454,801 $13.3 Million
Q4 2023

Jan 17, 2024

BUY
$19.97 - $24.53 $834,106 - $1.02 Million
41,768 Added 478.11%
50,504 $1.12 Million
Q2 2023

Jul 25, 2023

SELL
$21.38 - $29.19 $1.92 Million - $2.62 Million
-89,847 Reduced 91.14%
8,736 $247,000
Q1 2023

Apr 18, 2023

SELL
$21.74 - $30.93 $302,294 - $430,081
-13,905 Reduced 12.36%
98,583 $2.26 Million
Q4 2022

Jan 12, 2023

BUY
$24.81 - $31.52 $467,395 - $593,805
18,839 Added 20.12%
112,488 $3.16 Million
Q3 2022

Oct 27, 2022

SELL
$19.51 - $34.14 $305,390 - $534,393
-15,653 Reduced 14.32%
93,649 $2.65 Million
Q2 2022

Jul 27, 2022

BUY
$17.06 - $31.42 $1.86 Million - $3.43 Million
109,302 New
109,302 $2.42 Million
Q3 2020

Oct 07, 2020

SELL
$33.87 - $55.93 $1.74 Million - $2.88 Million
-51,412 Closed
0 $0
Q2 2020

Jul 21, 2020

BUY
$34.45 - $53.48 $1.77 Million - $2.75 Million
51,412 New
51,412 $2.75 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $3.05B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.